Septic shock

Lancet

Volumn 351, Issue 9114, 1998, Pages 1501-1505

  Astiz, Mark E ^a   Rackow, Eric C ^a  

^a ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN;

CAUSE OF DEATH; CLINICAL FEATURE; DISEASE COURSE; HEMODYNAMICS; HUMAN; HYPOTENSION; INTENSIVE CARE; METABOLISM; PATHOPHYSIOLOGY; PERFUSION; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 0032537394     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)01134-9     Document Type: Review

References (43)

1. 1 ACCP-SCCM Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
2. 2 Rangel-Frausto M, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273: 117-23.
3. 3 Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA 1995; 273: 934-41.
4. 4 Opal S, Fisher C, Dhainaut J. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomised, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115-24.
5. 5 Bone RC. Immunologic dissonance: a continuing evolutin in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunctin syndrome (MODS). Ann Intern Med 1996; 125: 60-87.
6. 6 Java R, Solomkin J. Cellular effectors of the septic process. In: Fein A, ed. Sepsis and multiorgan failure. Baltimore, USA: Williams and Wilkins, 1997; 74-99.
7. 7 Dinarello C. Cytokines as mediators in the pathogenesis of septic shock. Curr Topics Microbiol Immunol 1996; 216: 133-65.
8. 8 Cobb J, Danner R. Nitroc oxide and septic shock. JAMA 1996; 275: 1192-96.
9. 9 Lorente J, Landin L, Pablo R, Renes E, Liste E. L-arginine pathway in sepsis syndrome. Crit Care MEd 1993; 21: 1287-95.
10. 10 Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 831-36.
11. 11 Astiz M, De Gent G, Lin R, Rackow E. Microvascular function and rheologic changes in hyperdynamic sepsis. Crit Care Med 1995; 23: 265-71.
12. 12 Cowley H, Heney D, Gearing A, Hemingway I, Webster N. Increased circulating adhesion molecule concentrations in patients with the systemic inflammatory response syndrome: a prospective cohort study. Crit Care Med 1994; 22: 651-57.
13. 13 Levi M, ten Cate H, Van der Poll T, van Deventer J. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-79.
14. 14 Astiz M, Saha D, Lustbader D, Rackow E. Monocyte response to bacterial toxins, expression of cell surface antigens, and the release of anti-inflammatory cytokines. J Lab Clin Med 1996; 128: 594-600.
15. 15 Munoz C, Carlet C, Fitting B, Bleriot J, Cavaillon J. Dysregulation of in vitro cytokine productin by monocytes during sepsis. J Clin Invest 1991; 88: 1747-54.
16. 16 Bersten A, Hersch M, Cheung H, Rutledge F, Sibbald W. The effect of various sympathomimetics on the regional circulations in hyperdynamic sepsis. Surg 1992; 112: 549-61.
17. 17 Lam C, Tyml K, Martin C, Sibbald W. Microvascular perfusion is impaired in a rat model of normotensive sepsis. J Clin Invest 1994; 94: 2077-83.
18. 18 Yodice P, Astiz M, Kurian B, Lin R, Rackow E. Neutrophil rheologic changes in septic shock. Am J Respir Crit Care Med 1997; 155: 38-423.
19. 19 Cunnion R, Schaer G, Parker M, Natanson C, Parrillo J. The coronary circulation in human septic shock. Circ 1986; 73: 637-44.
20. 20 Parrillo J, Burch C, Shelhammer J, et al. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 1985; 76: 1539-53.
21. 21 Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo J. Tumour necrosis factor alpha and interlukin-1 are responsible for in vitro myocardial depression induced by human septic shock. J Exp Med 1996; 183: 949-58.
22. 22 Silverman H, Penaranda R, Orens J, Lee N. Impaired β-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 1993; 21: 31-39.
23. 2 uptake during endootoxemia. J Appl Physiol 1988; 64: 2410-19.
24. 24 Dahn M, Lange P, Kubdell K, et al. Splanchnic and total body oxygen consumption differences in septic and injured patients. Surg 1987; 101: 69-80.
25. 25 Freidman G, Berlot G, Kahn R, Vincent J. Combined measurements of blood lactate concentrations and gastric intramucoasal pH in patients with severe sepsis. Crit Care Med 1995; 23: 1184-93.
26. 26 Astiz ME, Rackow E, Schumer W, Weil M. Early impairment of oxidative metabolism and energy production in severe sepsis. Circ Shock 1988; 26: 311-20.
27. 3 during lethal endotoxemia. J Surg Res 1991; 51: 382-91.
28. 28 Hayes M, Timmins A, Yau E, Palazzo M, Watson D, Hinds C. Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome. Crit Care Med 1997; 25: 926-36.
29. 29 Kreger B, Craven D, McCabe W. Gram-negative bacteremia IV: re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68: 344-55.
30. 30 Bakker J, Coffernils M, Leon M, et al. Blood lactate levels are superior to oxygen derived variables in predicting outcome in septic shock. Chest 1991; 99: 956-62.
31. 31 Tuschmidt J, Freid J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992; 102: 216-20.
32. 32 Heyland OK, Cook DJ, King D, Kernerman P, Brun-Biersson C. Maximizing oxygen delivery in critically ill patients: a methodologic appraisal of the evidence. Crit Care Med 1996; 24: 517-24.
33. 33 Packman M, Raclow EC. Optimum left heart filling pressures during fluid resuscitation of patients with hypovolemic and septic shock. Crit Care Med 1983; 11: 165-69.
34. 34 Rackow EC, Falk JL, Fein IA, et al. Fluid resuscitation in shock: a comparison of the cardiorespiratory effects of albumin, hetastarch and saline solutions in patients with hypovolemic shock. Crit Care Med 1983; 11: 839-50.
35. 35 Silverman H, Tuma P. Gastric tonometry in patients with sepsis: effects of dobutamine infusins and packed red blood cell transfusions. Chest 1992; 102: 184-88.
36. 36 Rudis M, Basha M, Zarowitz B. Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 1996; 24: 525-37.
37. 37 Neviere R, Matheiu D, Changnon JC, Lebleu N, Wattel F. The contrasting effects of dobutamine and dopamine on gastric musosal perfusion in septic patients. Am J Respir Crit Care Med 1996; 154: 1684-88.
38. 38 Levy B, Bollaert PE, Lucchelli JP, et al. Dobutamine improves the adequacy of gastric mucosal perfusion in epinephrine-treated septic shock. Crit Care Med 1997; 25: 1649-54.
39. 39 Marik P, Mohedin M. The contrasting effects of dopamine and norepinepherine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994; 272: 1354-57.
40. 40 Lynn W Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 1995; 20: 143-58.
41. 41 Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25: 1095-100.
42. 42 Bone RC. Why sepsis trials fail. JAMA 1996; 276: 565-66.
43. 43 Liu M, Slutsky A. Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Intern Care Med 1997; 23: 718-31.